European scientists find reason why AstraZeneca vaccine forms rare blood clots

 

 

European scientists have been studying the Astra Zeneca vaccine ever since a small number of those who were injected with the vaccine started developing blood clots. Researchers in Germany and Norway independently isolated what may be the cause of these blood clots and doctors are looking for ways to that may be found to treat them.

 

German researchers at Greifswald University Hospital released a statement on Friday saying that the AstraZeneca vaccine created a specific antibody in very few individuals who had been inoculated with it. The antibody activated the formation rare blood clots in the brain.

 

According to an independent study by a team of scientists in Norway, the vaccine activated a powerful immune response in the body. They found a certain antibody triggered this response.

 

Both these studies on the AstraZeneca vaccine corroborated the formation of a specific antibody. Doctors could possibly treat this with medical drugs. However, they may not be able to prevent the autoimmune response by the body to the antibody present in the vaccine.

 

The scientists mention that their studies are preliminary ones. However, these clots seem to appear more often in young women and the age group of most of the patients in whom the blood clots appeared was between 20 and 50 years.

 

Many countries had stopped using these vaccines despite reassurances from the World Health Organization and the European Medicines Agency that the advantages of the vaccine far outweigh its risks.

 

Now, many of these countries have lifted the temporary ban and are using the AstraZeneca vaccine.

 


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>